Clinical trials: Methylnaltrexone
Pancreatic Cancer
A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
This is an adaptive design study. During the first phase of the study, participants will be randomized in 2:1 ratio to receive either MNTX 450 milligrams (mg) once daily (QD) or placebo.
- Trial name
- NCT04083651
- Testing
- Methylnaltrexone bromide
- Where
- United States
- Sponsor
- Bausch Health Americas, Inc.
Opioid-induced Constipation
Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit
The purpose of this study is to determine if there will be a significantly higher incidence of a bowel movement with methylnaltrexone vs.
- Trial name
- MOVE-IT (NCT01050595)
- Testing
- Methylnaltrexone Bromide
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- St. John Health System, Michigan
Opioid-Induced Constipation
Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness
This study will evaluate the safety and efficacy of methylnaltrexone administered as subcutaneous injections in subjects who have opioid-induced constipation and an advanced illness.
- Trial name
- NCT00672477
- Testing
- Methylnaltrexone
- Where
- 60 sites in United States, Australia and 10 more
- Volunteers
- 237 people
- Sponsor
- Bausch Health Americas, Inc.
Advanced Illness Patients With Opioid Induced Constipation
A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients
To test the effectiveness of MNTX in advanced illness subjects.
- Trial name
- NCT00401362
- Testing
- SC Methylnaltrexone
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Bausch Health Americas, Inc.
Opioid-induced Constipation
Study of Methylnaltrexone in Opioid-Induced Constipation Patients
This is a multicenter, randomized, double-blind , placebo-controlled trail to investigate the safety and efficacy of subcutaneous methylnaltrexone for treating opioid-induced constipation in patients with advanced illness.
- Trial name
- NCT02574819
- Testing
- Methylnaltrexone (MNTX)
- Where
- 12 sites in China
- Volunteers
- 198 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pharyngeal Dysfunction, Pharyngeal Swallowing
Opioid-Induced Swallowing Dysfunction - The Impact of Bolus Volume
The purpose of the study is to evaluate the impact of different bolus volumes and viscosity on remifentanil-induced swallowing dysfunction in healthy volunteers.Hence, whether swallowing tasks can be done safer during sedation by…
- Trial name
- NCT03283020
- Testing
- RemifentanilMNTX
- Where
- Sweden
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Region Örebro County
Constipation
Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-Constipation
The primary purpose of this study is to evaluate the safety, efficacy, and tolerability of subcutaneous (injection beneath the skin) MOA-728 versus placebo in adult Asian subjects with opioid-induced constipation associated with…
- Trial name
- NCT00936884
- Testing
- Methylnaltrexone
- Where
- 6 sites in South Korea, Taiwan
- Volunteers
- 50 people
- Sponsor
- Bausch Health Americas, Inc.
Constipation Drug Induced
Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation
The purpose of this study is to compare the efficacy of subcutaneous versus oral mu-opioid receptor antagonist therapy in opioid induced constipation that is refractory to other bowel regimens.
- Trial name
- NCT03523520
- Testing
- Methylnaltrexone Bromide 150 mg Oral Tablet, Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1, Naloxegol 25 MG Oral Tablet
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Missouri-Columbia